Cite

HARVARD Citation

    Dougan, M. et al. (2022). A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load. Clinical infectious diseases. pp. e440-e449. [Online]. 
  
Back to record